IART Earnings Prediction
The chart below shows how IART performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IART sees a +2.70% change in stock price 10 days leading up to the earnings, and a -2.06% change 10 days following the report. On the earnings day itself, the stock moves by -1.68%. This data can give you a slight idea of what to expect for the next quarter's release.
IART Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
380.83M
-0.41%
-8.93%
Gross Margin
56.27%
-14.25%
-4.76%
Operating Margin
6.81%
-68.31%
-40.63%
Net Margin
-2.81%
-155.10%
-5.39%
EPS
-0.14
-158.33%
-12.50%
No Data Available
IART Earnings Analysis
Integra LifeSciences Holdings Corporation (IART.O) Earnings Conference Call
Positive
Third Quarter Revenues: Our third quarter revenues were $381 million.
Adjusted EPS Performance: We delivered adjusted EPS of $0.41.
Supply Chain Resolution Efforts: Our board and leadership team remain laser-focused on resolving supply challenges.
Fourth Quarter Revenue Projection: We expect revenues in a range of $441 million to $451 million for the fourth quarter, representing a reported growth range of 11.1% to 13.6%.
Sequential Revenue Increase: Our fourth quarter guidance reflects a step-up in sequential revenue driven by the resolution of the majority of the shipping holds.
Negative
Organic Revenue Decline: Organic revenue decreased by 8.6% year-over-year, indicating a significant decline in sales performance.
Earnings Per Share Decline: Adjusted EPS for the third quarter was $0.41, down 46% compared to 2023, reflecting a sharp drop in profitability.
Gross Margin Decline: Gross margins for the third quarter were 63%, down 160 basis points versus 2023, highlighting increased manufacturing inefficiencies.
Cash Flow Challenges: Operating cash flow for the third quarter was $22.5 million, while free cash flow was negative $7.2 million, indicating cash generation challenges.
Codman Specialty Surgical Decline: Organic growth in the Codman Specialty Surgical business was down 10.7%, primarily due to shipping holds, which limited revenue potential.
IART FAQs
How does IART typically perform around its earnings report dates?
Is Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IART Earning Call Sentiment
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IART.O
-3.15%Positive
The earnings call reveals several challenges: declining revenues, EPS, and margins due to supply issues, production inefficiencies, and shipping holds. Despite optimistic guidance for 2025, the current financial metrics are weak, and leverage is high. The Q&A section highlights management's evasive responses on supply disruptions and potential capital needs, raising concerns. The market cap indicates a mid-cap stock, which may react moderately. Overall, the sentiment leans negative, with potential for a -2% to -8% stock price decline.
